LENZ — Lenz Therapeutics Income Statement
0.000.00%
Last trade - 00:00- $813.11m
- $604.08m
- 31
- 25
- 70
- 37
Annual income statement for Lenz Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 13.5 | 60.4 | 106 | 135 | 58.6 |
| Operating Profit | -13.5 | -60.4 | -106 | -135 | -58.6 |
| Total Net Non Operating Interest Income / Expense | |||||
| Gain / Loss on Sale of Assets | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -68.4 | -70.8 | -101 | -125 | -49.8 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -68.4 | -70.8 | -101 | -125 | -49.8 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -68.4 | -70.8 | -101 | -125 | -49.8 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -68.4 | -70.8 | -101 | -125 | -49.8 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -8.24 | -17.1 | -12.9 | -7.67 | -2.34 |
| Dividends per Share | |||||
| Special Dividends per Share |